Advanced

Beyond prostate-specific antigen : Utilizing novel strategies to screen men for prostate cancer

Loeb, Stacy; Lilja, Hans LU and Vickers, Andrew (2016) In Current Opinion in Urology 26(5). p.459-465
Abstract

Purpose of review The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. Recent findings Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction... (More)

Purpose of review The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. Recent findings Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection. Summary Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
4kScore, PCA3, phi, prostate cancer markers, PSA
in
Current Opinion in Urology
volume
26
issue
5
pages
7 pages
publisher
Lippincott Williams & Wilkins
external identifiers
  • scopus:84973390117
  • wos:000380751100011
ISSN
0963-0643
DOI
10.1097/MOU.0000000000000316
language
English
LU publication?
yes
id
9017f677-197c-40d1-aac9-2cb9ab43c7d1
date added to LUP
2016-11-23 13:44:31
date last changed
2017-09-18 11:31:10
@article{9017f677-197c-40d1-aac9-2cb9ab43c7d1,
  abstract     = {<p>Purpose of review The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection. Recent findings Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection. Summary Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.</p>},
  author       = {Loeb, Stacy and Lilja, Hans and Vickers, Andrew},
  issn         = {0963-0643},
  keyword      = {4kScore,PCA3,phi,prostate cancer markers,PSA},
  language     = {eng},
  month        = {09},
  number       = {5},
  pages        = {459--465},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Current Opinion in Urology},
  title        = {Beyond prostate-specific antigen : Utilizing novel strategies to screen men for prostate cancer},
  url          = {http://dx.doi.org/10.1097/MOU.0000000000000316},
  volume       = {26},
  year         = {2016},
}